10:07 AM
Mar 13, 2018
 |  BC Extra  |  Financial News

Clinical hold sinks Advaxis shares

Advaxis Inc. (NASDAQ:ADXS) tumbled $0.26 (12%) to $1.95 on Tuesday after the company announced late Monday that FDA had placed a clinical hold on a Phase I/II trial of axalimogene filolisbac (ADXS11-001) (see BioCentury Extra, March 12).

The hold follows a patient's death on Feb. 27. Axalimogene filolisbac is a live Listeria monocytogenes-based immunotherapy expressing E7 transforming protein (Human papillomavirus-16; HpV16gp2).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD